Clinical Research Programs at Pacific Shores Medical Group
Click on diagnosis for more information or Call Irene at 562-590-0345 Ext. 266
| ANEMIA | |
| ANTI-NAUSEA | |
| BONE METASTASES* | |
| BREAST CANCER | |
| prevention adjuvant metastatic 1st line metastatic 2nd/3rd line |
|
| COLON AND RECTAL CANCER | |
| adjuvant metastatic 1st line metastatic 2nd/3rd line |
|
| ESOPHAGEAL/STOMACH | |
| HEAD AND NECK | |
| LUNG | |
| LYMPHOMA | |
| MELANOMA | |
| PANCREAS | |
| PROSTATE | |
| SOLID TUMORS | |
| THYROID | |
| * Metastatic | Cancer resulting from the spread of the primary tumor |
| **Adjuvant therapy | Anticancer drugs, hormones, radiation therapy or other medication given after surgery to prevent the cancer from coming back |
| A prospective, randomized, double-blind, stratified, multicenter, 2-arm trial of the continued efficacy and safety of Zometa® (every 4 weeks vs. every 12 weeks) in patients with documented bone metastases from breast cancer | |
A Phase III Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women with Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer. |
|
A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Phase 3 Study of Denosumab as Adjuvant Treatment for Women with Early-Stage Breast Cancer at High Risk of Recurrence (D-CARE) |
|
| Back to Top | |
| A Phase 2 Study of EZN-2208 (PEG-SN38) Administered With and Without Cetuximab in Patients with Metastatic Colorectal Carcinoma (mCRC). | |
| ESOPHAGEAL/STOMACH | |
| A Phase II Study of the mTOR inhibitor RAD001 in Previously Treated Patients with Unresectable or Metastatic Adenocarcinoma of the Esophagus and Stomach | |
| A Randomized, Double-Blind, Phase 3 Study of Docetaxel and Ramucirumab versus Docetaxel and Placebo in the Treatment of Stage IV Non-Small Cell Lung Cancer Following Disease Progression after One Prior Platinum Based Therapy | |
| A Phase 2 Study to Assess the Efficacy and Safety of CAL-101 in Patients with Indolent B-cell Non-Hodgkin Lymphoma Refractory to Rituximab and Alkylating Agents | |
| A Randomized Multicenter Study Comparing Pixantrone + Rituximab with Gemcitabine + Rituximab In Patients with Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed after Therapy with CHOP-R or an Equivalent Regimen and are lneligible for Stem Cell Transplant | |
| MULTIPLE MYELOMA | |
| An Open-Label, Dose Escalation, Multicenter Phase 1/2 Study of KW-2478 in Combination with Bortezomib in Subjects with Relapsed and/or Refractory Multiple Myeloma (ON HOLD) | |
| PANCREAS | |
| A Phase 2 Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-6624 Combined with Gemcitabine as First Line Treatment for Metastatic Pancreatic Adenocarcinoma. | |
| A Multicenter, Open-Label, Randomized, Phase II Trial of Adjuvant Dasatinib plus Gemcitabine versus Single-Agent Gemcitabine in Patients with Resected Pancreatic Adenocarcinoma | |
| A Randomized Phase III Study of Weekly ABI-007 plus Gemcitabine versus Gemcitabine Alone in Patients with metastatic Adenocarcinoma of the Pancreas | |
| PREVENTION NAUSEA | |
| PROSTATE | |
| A 48-Month Extension to the Randomized Double-blind, Placebo Controlled Study of the Effects of Pomegrate Extract on Rising Prostate-Specific Antigen Levels in Men following Primary Therapy for Prostate Cancer | |
| Back to Top | An Open-Label Extension Study Of The Effects Of Pomegranate Extract On Rising Prostatespecific Antigen Levels In Men Following Primary Therapy For Prostate Cancer |
| SOLID TUMOR | |
| An Open-label Treatment Extension Study of AMG 706 | |
| THYROID | |
| * Metastatic | Cancer resulting from the spread of the primary tumor |
| **Adjuvant therapy | Anticancer drugs, hormones, radiation therapy or other medication given after surgery to prevent the cancer from coming back |